ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

CARA Cara Therapeutics Inc

0.2893
-0.0007 (-0.24%)
27 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Cara Therapeutics Inc CARA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0007 -0.24% 0.2893 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.3001 0.2716 0.3198 0.3045 0.29
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/6/202415:16EDGAR2Form 8-K - Current report
12/6/202416:12EDGAR2Form 8-K - Current report
12/6/202415:01GLOBECara Therapeutics Announces Outcome of Part A of KOURAGE-1..
07/6/202415:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/6/202415:05EDGAR2Form 8-K - Current report
06/6/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202415:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202415:10EDGAR2Form 8-K - Current report
13/5/202415:01GLOBECara Therapeutics Reports First Quarter 2024 Financial..
06/5/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/5/202406:00GLOBECara Therapeutics to Announce First Quarter 2024 Financial..
02/4/202406:00GLOBECara Therapeutics to Present at the 23rd Annual Needham..
07/3/202406:00GLOBECara Therapeutics to Host Notalgia Paresthetica (NP) Virtual..
06/3/202415:45EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/3/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202415:10EDGAR2Form 8-K - Current report
04/3/202415:01GLOBECara Therapeutics Announces Fourth Quarter and Full Year..
13/2/202417:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202416:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202416:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202416:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202416:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:01GLOBECara Therapeutics to Announce Fourth Quarter and Full Year..
05/2/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:59EDGAR2Form 8-K - Current report
29/1/202414:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202415:19EDGAR2Form 8-K - Current report
22/1/202406:00GLOBECara Therapeutics Prioritizes Late-Stage Notalgia..
18/12/202306:10EDGAR2Form 8-K - Current report
18/12/202306:00GLOBECara Therapeutics Announces Outcome from Dose-Finding Part A..
13/11/202315:28EDGAR2Form 8-K - Current report
13/11/202315:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:11EDGAR2Form 8-K - Current report
13/11/202315:01GLOBECara Therapeutics Reports Third Quarter 2023 Financial..
03/11/202315:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202306:10EDGAR2Form 8-K - Current report
02/11/202306:00GLOBECara Therapeutics Announces up to $40.0 Million Non-Dilutive..
23/10/202306:00GLOBECara Therapeutics to Announce Third Quarter 2023 Financial..
25/9/202306:00GLOBECara Therapeutics Announces Approval of KORSUVA® IV..
05/9/202306:00GLOBECara Therapeutics to Present at the H.C. Wainwright 25th..
07/8/202315:24EDGAR2Form 8-K - Current report